Literature DB >> 9417120

Discrimination between RelA and RelB transcriptional regulation by a dominant negative mutant of IkappaBalpha.

V Ferreira1, N Tarantino, M Körner.   

Abstract

RelA and RelB belong to the nuclear factor-kappaB (NF-kappaB-Rel) transcription factor family. Both proteins are structurally and functionally related, but their intracellular and tissue distributions are different. In resting cells, RelB is found mostly in the nucleus, whereas RelA is sequestered in the cytosol by protein inhibitors, among which IkappaBalpha is the dominant form in lymphocytes. Upon cellular activation IkappaBalpha is proteolyzed, allowing RelA dimers to enter the nucleus and activate target genes. To study the selectivity of gene regulation by RelA and RelB, we generated T cell lines stably expressing a dominant negative mutant of IkappaBalpha. We show that selective inhibition of RelA-NF-kappaB decreased induction of NFKB1, interleukin-2, and interleukin-2Ralpha genes but not c-myc. Transcription driven by the IkappaBalpha promoter was blocked by the transgenic IkappaBalpha; however, wild type IkappaBalpha was expressed in the transgenic cell clones but with much slower kinetics than that in control cells. Wild type IkappaBalpha expression was concomitant with RelB up-regulation, suggesting that RelB could be involved in transcription of IkappaBalpha through binding to an alternative site. These results indicate that RelB and RelA have both distinct and overlapping effects on gene expression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9417120     DOI: 10.1074/jbc.273.1.592

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  RelB nuclear translocation regulates B cell MHC molecule, CD40 expression, and antigen-presenting cell function.

Authors:  B J O'Sullivan; K P MacDonald; A R Pettit; R Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

2.  Ikappakappa mediates NF-kappaB activation in human immunodeficiency virus-infected cells.

Authors:  S Asin; J A Taylor; S Trushin; G Bren; C V Paya
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  RelB modulation of IkappaBalpha stability as a mechanism of transcription suppression of interleukin-1alpha (IL-1alpha), IL-1beta, and tumor necrosis factor alpha in fibroblasts.

Authors:  Y Xia; S Chen; Y Wang; N Mackman; G Ku; D Lo; L Feng
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

4.  Attenuated and lethal variants of Pichindé virus induce differential patterns of NF-kappaB activation suggesting a potential target for novel therapeutics.

Authors:  Gavin C Bowick; Susan M Fennewald; Lihong Zhang; Xianbin Yang; Judith F Aronson; Robert E Shope; Bruce A Luxon; David G Gorenstein; Norbert K Herzog
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

Review 5.  Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target.

Authors:  Jianbiao Zhou; Ying Qing Ching; Wee-Joo Chng
Journal:  Oncotarget       Date:  2015-03-20

6.  Using a novel in vivo model to study the function of nuclear factor kappa B in cerebral ischemic injury.

Authors:  Rui Wang; Songlan Liang; Hui Yue; Lijie Chen
Journal:  Med Sci Monit       Date:  2012-11

7.  Small ubiquitin-related modifier 1 is involved in hepatocellular carcinoma progression via mediating p65 nuclear translocation.

Authors:  Jun Liu; Xiaofang Tao; Jin Zhang; Peng Wang; Manqi Sha; Yong Ma; Xiaoping Geng; Lijie Feng; Yujun Shen; Yifan Yu; Siying Wang; Shengyun Fang; Yuxian Shen
Journal:  Oncotarget       Date:  2016-04-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.